- Home
- CMPO vs NRIX Comparison
CMPO vs NRIX Comparison
Compare CMPO & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMPO
- NRIX
- Stock Information
- Founded
- CMPO 2000
- NRIX 2009
- Country
- CMPO United States
- NRIX United States
- Employees
- CMPO N/A
- NRIX N/A
- Industry
- CMPO Finance: Consumer Services
- NRIX Biotechnology: Pharmaceutical Preparations
- Sector
- CMPO Finance
- NRIX Health Care
- Exchange
- CMPO Nasdaq
- NRIX Nasdaq
- Market Cap
- CMPO 1.2B
- NRIX 1.1B
- IPO Year
- CMPO N/A
- NRIX 2020
- Fundamental
- Price
- CMPO $10.94
- NRIX $12.15
- Analyst Decision
- CMPO Strong Buy
- NRIX Strong Buy
- Analyst Count
- CMPO 8
- NRIX 17
- Target Price
- CMPO $16.19
- NRIX $30.82
- AVG Volume (30 Days)
- CMPO 1.2M
- NRIX 946.2K
- Earning Date
- CMPO 03-05-2025
- NRIX 04-09-2025
- Dividend Yield
- CMPO 2.28%
- NRIX N/A
- EPS Growth
- CMPO N/A
- NRIX N/A
- EPS
- CMPO N/A
- NRIX N/A
- Revenue
- CMPO $420,571,000.00
- NRIX $54,549,000.00
- Revenue This Year
- CMPO $8.91
- NRIX $1.77
- Revenue Next Year
- CMPO $8.74
- NRIX $6.62
- P/E Ratio
- CMPO N/A
- NRIX N/A
- Revenue Growth
- CMPO 7.67
- NRIX N/A
- 52 Week Low
- CMPO $4.97
- NRIX $11.90
- 52 Week High
- CMPO $14.71
- NRIX $29.56
- Technical
- Relative Strength Index (RSI)
- CMPO 40.12
- NRIX 30.68
- Support Level
- CMPO $11.02
- NRIX $12.20
- Resistance Level
- CMPO $11.91
- NRIX $13.10
- Average True Range (ATR)
- CMPO 0.43
- NRIX 0.77
- MACD
- CMPO 0.06
- NRIX 0.01
- Stochastic Oscillator
- CMPO 38.22
- NRIX 5.23
About CMPO CompoSecure Inc.
CompoSecure Inc is engaged in designing and manufacturing premium financial cards. The Company's metal payment card technology and Arculus security and authentication capabilities deliver premium branded experiences which enable people to access and use their assets, and ensure trust at the point of a transaction. Its products include Metal Cards and Arculus, a digital security platform. It has two reportable segments: Payment Card and Arculus.
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.